Clemens Metze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Clemens Metze has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Christos Iliadis
Department of Cardiology, Heart Center Cologne University of Cologne, Faculty of Medicine and University Hospital Cologne Germany
2 shared publicationsRoman Pfister
Department of Cardiology, Heart Center Cologne University of Cologne, Faculty of Medicine and University Hospital Cologne Germany
2 shared publicationsStephan Baldus
Department of Cardiology, Heart Center Cologne University of Cologne, Faculty of Medicine and University Hospital Cologne Germany
2 shared publications- Alev Kalkan
Department III of Internal medicine, Heart Center, University Hospital of Cologne, Cologne, Germany
1 shared publication Amin Polzin
Division of Cardiology, Pulmonology and Vascular Medicine Heinrich Heine University, Medical Faculty Düsseldorf Germany
1 shared publication- Christopher Hohmann
University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department III of Internal Medicine, Heart Center, Kerpener Straße 62, D-50931, Cologne, Germany
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (6) , e70138
A Simplified Frailty Measure Improves Risk Stratification in Patients Undergoing Percutaneous Mitral Valve Repair
Objective: The aim of this study was to examine frailty measures for risk prediction in patients undergoing percutaneous mitral valve repair (PMVR). Background: Performance of current risk prediction models based on organ morbidity is only moderate. Methods: The frailty domains exhaustion, slowness, inactivity, weakness, and unintentional weight loss were prospectively assessed in patients undergoing PMVR. The association with mortality and heart failure hospitalization (HFH) during a median follow‐up of 506 days was examined and relevant domains were assessed for additive predictive performance over the MitraScore. Results: Five hundred twenty‐four patients were included in the study (mean age [SD]: 77 (9) years, 54.6% male). The risk of mortality and mortality/HFH were significantly increased in patients with exhaustion (hazard ratio: 2.24 [95% CI: 1.63–3.08]/1.83 [1.21–2.77]), slowness (2.74 [1.75–4.30]/1.92 [1.34–2.75]), inactivity (1.96 [1.26–3.05]/1.61 [1.12–2.31]) and weakness (1.83 [1.12–2.96]/1.34 [0.92–1.95]), but not in patients with weight loss (1.24 [0.80–1.92]/1.12 [0.78–1.61]). A simplified frailty (S‐frailty) measure derived from the domains exhaustion and slowness was associated with mortality (4.45 [2.42–8.19]) and mortality/HFH (2.60 [1.64–4.13]) independently of clinical risk factors and the MitraScore, respectively. Prediction of mortality by the MitraScore was significantly improved when adding S‐frailty (Harrell's C 0.645 vs. 0.700, p = 0.002). Classification of 1‐year mortality risk by the MitraScore improved when adding S‐frailty (net reclassification index 0.21, p = 0.012 and integrated discrimination index 0.07, p < 0.001). Conclusions: A simplified frailty measure comprising self‐reported exhaustion and gait speed significantly improved risk prediction in patients undergoing PMVR. Assessment of frailty measures should be part of the decision‐making process and multiparametric risk scores in patients with severe mitral regurgitation.
- 1 December 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (6) , e70138
Open AccessA Simplified Frailty Measure Improves Risk Stratification in Patients Undergoing Percutaneous Mitral Valve Repair
Objective: The aim of this study was to examine frailty measures for risk prediction in patients undergoing percutaneous mitral valve repair (PMVR). Background: Performance of current risk prediction models based on organ morbidity is only moderate. Methods: The frailty domains exhaustion, slowness, inactivity, weakness, and unintentional weight loss were prospectively assessed in patients undergoing PMVR. The association with mortality and heart failure hospitalization (HFH) during a median follow‐up of 506 days was examined and relevant domains were assessed for additive predictive performance over the MitraScore. Results: Five hundred twenty‐four patients were included in the study (mean age [SD]: 77 (9) years, 54.6% male). The risk of mortality and mortality/HFH were significantly increased in patients with exhaustion (hazard ratio: 2.24 [95% CI: 1.63–3.08]/1.83 [1.21–2.77]), slowness (2.74 [1.75–4.30]/1.92 [1.34–2.75]), inactivity (1.96 [1.26–3.05]/1.61 [1.12–2.31]) and weakness (1.83 [1.12–2.96]/1.34 [0.92–1.95]), but not in patients with weight loss (1.24 [0.80–1.92]/1.12 [0.78–1.61]). A simplified frailty (S‐frailty) measure derived from the domains exhaustion and slowness was associated with mortality (4.45 [2.42–8.19]) and mortality/HFH (2.60 [1.64–4.13]) independently of clinical risk factors and the MitraScore, respectively. Prediction of mortality by the MitraScore was significantly improved when adding S‐frailty (Harrell's C 0.645 vs. 0.700, p = 0.002). Classification of 1‐year mortality risk by the MitraScore improved when adding S‐frailty (net reclassification index 0.21, p = 0.012 and integrated discrimination index 0.07, p < 0.001). Conclusions: A simplified frailty measure comprising self‐reported exhaustion and gait speed significantly improved risk prediction in patients undergoing PMVR. Assessment of frailty measures should be part of the decision‐making process and multiparametric risk scores in patients with severe mitral regurgitation.
- Open Access
- 4 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 284
Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment
Background: Recently, a disease modifying therapy has become available for transthyretin amyloid cardiomyopathy (ATTR-CM). A validated monitoring concept of treatment is lacking, but a current expert consensus recommends three clinical domains (clinical, biomarker and ECG/imaging) assessed by several measurable features to define disease progression. Methods: We retrospectively analyzed data of wild-type ATTR-CM patients initiating tafamidis therapy assessed within our local routine protocol at baseline and 6-months follow-up with respect to the frequency of values beyond the proposed thresholds defining disease progression. Additionally, associations of cardiac magnetic resonance (CMR) tomography with clinical domains were examined within a subgroup. Results: Sixty-two ATTR-CM patients were included (88.7% male, mean age 79 years). In total, 16.1% of patients had progress in the clinical and functional domain, 33.9% in the biomarker domain and 43.5% in the imaging/electrocardiography (ECG) domain, with the latter driven by deterioration of the diastolic dysfunction grade and global longitudinal strain. In total, 35.5% of patients showed progress in none, 35.5% in one, 29.0% in two and no patient in three domains, the latter indicating overall disease progression. A subgroup analysis of twenty-two patients with available baseline and follow-up CMR data revealed an increase in CMR-based extracellular volume by more than 5% in 18.2% of patients, with no significant correlation with progress in one of the clinical domains. Conclusions: We provide first frequency estimates of the markers of disease progression according to a recent expert consensus statement, which might help refine the multiparametric monitoring concept in patients with ATTR-CM.
- 4 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 284
Open AccessMultiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment
Background: Recently, a disease modifying therapy has become available for transthyretin amyloid cardiomyopathy (ATTR-CM). A validated monitoring concept of treatment is lacking, but a current expert consensus recommends three clinical domains (clinical, biomarker and ECG/imaging) assessed by several measurable features to define disease progression. Methods: We retrospectively analyzed data of wild-type ATTR-CM patients initiating tafamidis therapy assessed within our local routine protocol at baseline and 6-months follow-up with respect to the frequency of values beyond the proposed thresholds defining disease progression. Additionally, associations of cardiac magnetic resonance (CMR) tomography with clinical domains were examined within a subgroup. Results: Sixty-two ATTR-CM patients were included (88.7% male, mean age 79 years). In total, 16.1% of patients had progress in the clinical and functional domain, 33.9% in the biomarker domain and 43.5% in the imaging/electrocardiography (ECG) domain, with the latter driven by deterioration of the diastolic dysfunction grade and global longitudinal strain. In total, 35.5% of patients showed progress in none, 35.5% in one, 29.0% in two and no patient in three domains, the latter indicating overall disease progression. A subgroup analysis of twenty-two patients with available baseline and follow-up CMR data revealed an increase in CMR-based extracellular volume by more than 5% in 18.2% of patients, with no significant correlation with progress in one of the clinical domains. Conclusions: We provide first frequency estimates of the markers of disease progression according to a recent expert consensus statement, which might help refine the multiparametric monitoring concept in patients with ATTR-CM.
- Open Access
- 15 August 2023
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 113 (1) , 94-106
Prognostic impact of cancer history in patients undergoing transcatheter mitral valve repair
Background: History of cancer is common in patients undergoing transcatheter mitral valve repair (TMVR). Objectives: Aim was to examine the impact of cancer history on outcomes after TMVR. Methods: In patients of a monocentric prospective registry of TMVR history of cancer was retrospectively assessed from records. Associations with 6-week functional outcomes and clinical outcomes during a median follow-up period of 594 days were examined. Results: Of 661 patients (mean age 79 years; age-range 37–101 years; 56.1% men), 21.6% had a history of cancer with active disease in 4.1%. Compared with non-cancer patients, cancer patients had a similar procedural success rate (reduction of mitral regurgitation to grade 2 or lower 91.6% vs. 88%; p = 0.517) and similar relevant improvement in 6-min walking distance, NYHA class, Minnesota Living with Heart Failure Questionnaire score and Short Form 36 scores. 1-year survival (83% vs. 82%; p = 0.813) and 1-year survival free of heart failure decompensation (75% vs. 76%; p = 0.871) were comparable between cancer and non-cancer patients. Patients with an active cancer disease showed significantly higher mortality compared with patients having a history of cancer (hazard ratio 2.05 [95% CI 1.11–3.82; p = 0.023]) but similar mortality at landmark analysis of 1 year. Conclusion: TMVR can be performed with equal efficacy in patients with and without cancer and symptomatic mitral regurgitation. Cancer patients show comparable clinical outcome and short-term functional improvement as non-cancer patients. However, longterm mortality was increased in patients with active cancer underlining the importance of patient selection within the heart-team evaluation. Graphical
- 15 August 2023
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 113 (1) , 94-106
Open AccessPrognostic impact of cancer history in patients undergoing transcatheter mitral valve repair
Background: History of cancer is common in patients undergoing transcatheter mitral valve repair (TMVR). Objectives: Aim was to examine the impact of cancer history on outcomes after TMVR. Methods: In patients of a monocentric prospective registry of TMVR history of cancer was retrospectively assessed from records. Associations with 6-week functional outcomes and clinical outcomes during a median follow-up period of 594 days were examined. Results: Of 661 patients (mean age 79 years; age-range 37–101 years; 56.1% men), 21.6% had a history of cancer with active disease in 4.1%. Compared with non-cancer patients, cancer patients had a similar procedural success rate (reduction of mitral regurgitation to grade 2 or lower 91.6% vs. 88%; p = 0.517) and similar relevant improvement in 6-min walking distance, NYHA class, Minnesota Living with Heart Failure Questionnaire score and Short Form 36 scores. 1-year survival (83% vs. 82%; p = 0.813) and 1-year survival free of heart failure decompensation (75% vs. 76%; p = 0.871) were comparable between cancer and non-cancer patients. Patients with an active cancer disease showed significantly higher mortality compared with patients having a history of cancer (hazard ratio 2.05 [95% CI 1.11–3.82; p = 0.023]) but similar mortality at landmark analysis of 1 year. Conclusion: TMVR can be performed with equal efficacy in patients with and without cancer and symptomatic mitral regurgitation. Cancer patients show comparable clinical outcome and short-term functional improvement as non-cancer patients. However, longterm mortality was increased in patients with active cancer underlining the importance of patient selection within the heart-team evaluation. Graphical